Prominent publications by Joanne M Donovan

KOL Index score: 13601

BACKGROUND: Colesevelam hydrochloride is a novel, lipid-lowering agent that binds bile acids with high affinity. A multicenter, randomized, double-blind, placebo-controlled, parallel-design study was conducted to assess the efficacy and tolerability of combination low-dose colesevelam and lovastatin treatment in patients with primary hypercholesterolemia.

HYPOTHESIS: Combination therapy with low doses of colesevelam and lovastatin decreases low density (LDL) cholesterol with minimal ...

Known for Colesevelam Hydrochloride |  Primary Hypercholesterolemia |  Combination Therapy |  Lovastatin Dinner |  Density Lipoprotein
KOL Index score: 12379

BackgroundColesevelam is a bile acid sequestrant that differs structurally from traditional bile acid sequestrants, allowing it to bind bile acids with greater affinity. Studies have shown that colesevelam significantly reduces low-density lipoprotein cholesterol (LDL-C) levels and, in some cases, significantly increases high-density lipoprotein cholesterol (HDL-C) levels in adults with primary hypercholesterolemia.ObjectiveTo investigate the safety and efficacy of colesevelam in adults ...

Known for Hdl Cholesterol |  Ldlc Levels |  Ldl Colesevelam |  375 Day |  Bile Acid
KOL Index score: 11641

AIMS: A randomized, double-blind, placebo-controlled study was conducted to investigate the safety and efficacy of mipomersen, an apolipoprotein B-100 (apoB) synthesis inhibitor, in patients who are statin intolerant and at high risk for cardiovascular disease (CVD).

METHODS AND RESULTS: Thirty-three subjects, not receiving statin therapy because of statin intolerance, received a weekly subcutaneous dose of 200 mg mipomersen or placebo (2:1 randomization) for 26 weeks. The primary ...

Known for Intolerant Patients |  Placebo Mipomersen |  Lipoprotein Cholesterol |  Risk Cvd |  26 Weeks
KOL Index score: 11164

BACKGROUND: Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery disease. Despite statins and additional lipid-lowering therapies, many HeFH patients fail to achieve low-density lipoprotein cholesterol (LDL-C) goals. We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, to further lower LDL-C in HeFH patients with coronary artery disease.

METHODS AND RESULTS: This double-blind, placebo-controlled, phase 3 trial ...

Known for Hefh Patients |  Mipomersen Ldlc |  Heterozygous Familial |  Hepatic Fat |  Coronary Artery Disease
KOL Index score: 10939

PURPOSE: To examine the efficacy and safety of colesevelam hydrochloride, a novel, nonsystemic, lipid-lowering agent, when coadministered with starting doses of simvastatin in a multicenter, randomized, double-blind, placebo-controlled trial.

PATIENTS AND METHODS: Subjects with hypercholesterolemia (plasma low density lipoprotein [LDL] cholesterol level > 160 mg/dL and triglyceride level < or = 300 mg/dL) were randomly assigned to receive daily doses of placebo (n = 33), colesevelam 3.8 ...

Known for Combination Simvastatin |  Primary Hypercholesterolemia |  Hdl Cholesterol |  Efficacy Safety |  Colesevelam Patients
KOL Index score: 10862

Colesevelam hydrochloride is a novel, potent, non-absorbed lipid-lowering agent previously shown to reduce low density lipoprotein (LDL) cholesterol. To examine the efficacy and safety of coadministration of colesevelam and atorvastatin, administration of these agents alone or in combination was examined in a double-blind study of 94 hypercholesterolemic men and women (baseline LDL cholesterol > or =160 mg/dl). After 4 weeks on the American Heart Association Step I diet, patients were ...

Known for Colesevelam Hydrochloride |  Hdl Cholesterol |  4 Weeks |  Combination Therapy |  Agents Atorvastatin
KOL Index score: 8584

OBJECTIVE: To evaluate the efficacy, tolerability, and safety of colesevelam hydrochloride, a new nonsystemic lipid-lowering agent.

PATIENTS AND METHODS: In this double-blind, placebo-controlled trial performed in 1998, 494 patients with primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol level > or = 130 mg/dL and < or = 220 mg/dL) were randomized to receive placebo or colesevelam (2.3 g/d, 3.0 g/d, 3.8 g/d, or 4.5 g/d) for 24 weeks. Fasting serum lipid profiles were ...

Known for Colesevelam Hydrochloride |  Primary Hypercholesterolemia |  Cholesterol Ldl |  Randomized Controlled |  Dosedependent Manner
KOL Index score: 5632

Although colesevelam hydrochloride (HCl) is indicated to reduce low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and improve glycemic control in patients with type 2 diabetes, its effects on glucose and lipids in patients with prediabetes have not been previously studied. To evaluate the effects of colesevelam HCl in patients with prediabetes, a post-hoc analysis was conducted on data from a 24-week lipid-lowering study. Using baseline laboratory safety data ...

Known for Colesevelam Hcl |  Plasma Glucose |  Glycemic Control |  Cholesterol Ldl |  Type 2 Diabetes
KOL Index score: 4617

Colesevelam HCl is a potent bile acid–binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol Education Program diet for 6 weeks and were randomized to colesevelam HCl, 2.3 or 3.8 g/day for 4 weeks. In ...

Known for Colesevelam Hcl |  Bile Acid |  6 Weeks |  Cholesterol Ldl |  Density Lipoprotein
KOL Index score: 3555

BACKGROUND: Because of variability in lipoprotein cholesterol content, low-density lipoprotein (LDL) cholesterol frequently underrepresents or overrepresents the number of LDL particles. Mipomersen is an antisense oligonucleotide that reduces hepatic production of apolipoprotein B-100, the sole apolipoprotein of LDL.

OBJECTIVE: To characterize the effects of mipomersen on lipoprotein particle numbers as well as subclass distribution using nuclear magnetic resonance (NMR) ...

Known for Density Lipoprotein |  Cholesterol Ldl |  Coronary Heart Disease |  Compared Small |  Antisense Oligonucleotide
KOL Index score: 1956

Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. Preclinical pharmacology studies demonstrate iron excretion largely by the fecal route. Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency and safety of deferitrin.

Known for Iron Chelator |  Molecular Structure |  Chelating Agents |  Chelation Therapy |  Administration Oral


Joanne M Donovan: Influence Statistics

Sample of concepts for which Joanne M Donovan is among the top experts in the world.
Concept World rank
subjects colesevelam #4

Key People For Colesevelam Hcl

Top KOLs in the world
Michael H Davidson
hdl cholesterol schizophrenic patients cognitive impairment
Donald B Hunninghake
hdl cholesterol coronary heart disease lipoprotein levels
Harold Edward Bays
bempedoic acid icosapent ethyl diabetes mellitus
Steven K Burke
sevelamer hydrochloride serum phosphorus hemodialysis patients
Phillip D Toth
colesevelam hydrochloride obese patients moderate hypertension
hdl cholesterol corneal arcus delayed adolescence

Joanne M Donovan:Expert Impact

Concepts for whichJoanne M Donovanhas direct influence:Colesevelam hcl,  Primary hypercholesterolemia,  Colesevelam hydrochloride,  Hdl cholesterol,  Plasma glucose,  Cholesterol ldl,  Bile acid,  Subjects colesevelam.

Joanne M Donovan:KOL impact

Concepts related to the work of other authors for whichfor which Joanne M Donovan has influence:Familial hypercholesterolemia,  Colesevelam hcl,  Statin therapy,  Type 2 diabetes,  Bile acid sequestrants,  Cholesterol ldl,  Density lipoprotein.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Genzyme Corporation, Cambridge, MA, USA | Genzyme Corporation, Cambridge, MA 02142, USA | From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Clinical Research Institute of Montréal, Montréal, Québec, Canada (R.D.); Clini

FREE Custom List